As there are currently limited drugs that can treat WMH caused by CCH, the decreased expression of MATK in peripheral blood found in our study is a biomarker in CCH patients with WMH, so MATK may become a potential target for treating WMH in patients with CCH. This evidence concerns the gene MATK and columnar cell hyperplasia of the breast.